Pharmaceutical compositions and methods
Pharmaceutical compositions and kits including a tyrosine hydroxylase inhibitor; melanin, a melanin promoter, or a combination thereof; a p450 3A4 promoter; and a leucine aminopeptidase inhibitor are provided. Also provided are methods of treating cancer in a subject, comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof. Also provided are methods of reducing cell proliferation in a subject comprising administering an effective amount of a tyrosine hydroxylase inhibitor, a melanin promoter, a p450 3A4 promoter, and a leucine aminopeptidase inhibitor to the subject in need thereof.
1. A pharmaceutical composition comprising: a tyrosine hydroxylase inhibitor that is
methyl (2R)-2-amino-3-(2-chloro-4-hydroxyphenyl) propanoate, D-tyrosine ethyl ester hydrochloride, methyl (2R)-2-amino-3-(2,6-dichloro-3,4-dimethoxyphenyl) propanoate, H-D-Tyr(TBU)-allyl ester HCl, methyl (2R)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(4-[(2-chloro-6-fluorophenyl)methoxy] phenyl) propanoate, methyl (2R)-2-amino-3-(2-chloro-3,4-dimethoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl) propanoate, diethyl 2-(acetylamino)-2-(4-[(2-chloro-6-fluorobenzyl)oxy] benzyl malonate, methyl (2R)-2-amino-3-(3-chloro-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxy-5-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(2,6-dichloro-3-hydroxy-4-methoxyphenyl) propanoate, methyl (2R)-2-amino-3-(3-chloro-4-hydroxyphenyl) propanoate, DL-tyr-OMe HCl, H-3,5-diiodo-tyr-OMe HCl, H-D-3,5-diiodo-tyr-OMe HCl, H-D-tyr-OMe HCl, D-tyrosine methyl ester hydrochloride, methyl D-tyrosinate hydrochloride, (2R)-2-amino-3-(4-hydroxyphenyl) propionic acid, (2R)-2-amino-3-(4-hydroxyphenyl) methyl ester hydrochloride, methyl (2R)-2-amino-3-(4-hydroxyphenyl) propanoate hydrochloride, methyl(2R)-2-azanyl-3-(4-hydroxyphenyl) propanoate hydrochloride, 3-chloro-L-tyrosine, 3-nitro-L-tyrosine, 3-nitro-L-tyrosine ethyl ester hydrochloride, DL-m-tyrosine, DL-o-tyrosine, Boc-Tyr (3,5-12)-OSu, Fmoc-tyr(3-NO 2 )—OH, or α-methyl-DL-tyrosine; and
melanin, a melanin promoter that is methoxsalen or melanotan II, or a combination of melanin, methoxsalen and melanotan II.
2. The pharmaceutical composition of claim 1 , wherein said tyrosine hydroxylase inhibitor is α-methyl-DL-tyrosine.
3. The pharmaceutical composition of claim 1 , comprising melanin.
4. The pharmaceutical composition of claim 1 , further comprising a p450 3A4 promoter that is 5,5-diphenylhydantoin, valproic acid, or carbamazepine; and a leucine aminopeptidase inhibitor that is N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine, or rapamycin.
5. The pharmaceutical composition of claim 4 , comprising melanotan II.
6. The pharmaceutical composition of claim 4 , wherein said p450 3A4 promoter is 5,5-diphenylhydantoin.
7. The pharmaceutical composition of claim 4 , wherein said leucine aminopeptidase inhibitor is rapamycin or N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine.
8. The pharmaceutical composition of claim 1 , further comprising a p450 3A4 promoter.
9. The pharmaceutical composition of claim 8 , wherein said p450 3A4 promoter is 5,5-diphenylhydantoin.
10. The pharmaceutical composition of claim 1 , further comprising a leucine aminopeptidase inhibitor.
11. The pharmaceutical composition of claim 10 , wherein said leucine aminopeptidase inhibitor is rapamycin or N-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyryl]-L-leucine.